PR Newswire: news distribution, targeting and monitoring
2014

Atossa Genetics, Inc. Sued by Investors After Stock Drops 46% on Drug Recall

Share with Twitter Share with LinkedIn

SAN DIEGO and SEATTLE, Oct. 14, 2013 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Atossa Genetics, Inc. (NASDAQ: ATOS) has filed a federal securities fraud class action complaint in the U.S. District Court, Western District of Washington.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between November 8, 2012 and October 4, 2013 (the "Class Period").    

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Learn more about our investigation on our Shareholder Rights Blog: http://www.robbinsarroyo.com/shareholders-rights-blog/atossa-genetics-inc/

Atossa Accused of Failing to Disclose Material Adverse Facts to Investors Regarding its MASCT System and MASCT System Collection Test (collectively, the "MASCT System")

Shares of Atossa fell $2.47 per share, or more than 46%, on October 4, 2013, after the company announced "a voluntary recall to remove the ForeCYTE Breast Health Test and the Mammary Aspiration Specimen Cytology Test (MASCT) device from the market." This steep decline follows an initial 5.6% decline per share on February 25, 2013, following the announcement that the company received a warning letter from the U.S. Food and Drug Administration ("FDA") regarding the MASCT System.

According to the complaint, Atossa made false and/or misleading statements, as well as failed to disclose the following material adverse facts about its business and financial condition.  Atossa was:

  • required, but failed, to submit an additional 510(k) notification to obtain necessary FDA clearance as it made material changes to the Nipple Aspirate Fluid specimen collection process;
  • improperly marketing its devices by using certain promotional claims to market the ForeCYTE Breast Health Test and the MASCT device; and
  • was in violation of FDA Good Manufacturing Practices regulations.

If you invested in Atossa and would like to discuss your shareholder rights please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.  

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP



RELATED LINKS
http://www.robbinsarroyo.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release